
Solving drug shortages through dedicated manufacturing

CIVICA

Through our new, 140K square foot state-of-the-art essential medicines manufacturing facility,* we will ensure availability, quality and affordability.



Civica Rx entered the manufacturing realm to have a direct impact on drug shortages. With a new state-of-the-art sterile injectable manufacturing facility in Virginia,* Civica will produce a reliable supply of more than three dozen drugs currently in or near shortage status.



New isolator-integrated vial filling and nested filling lines allow pivoting to produce many different forms of injectables based on greatest need.

Multiple vial sizes can be processed, including 2R (2mL) and multiple configurations for 10 mL vials.

More than 200 million units can be produced annually across three

production lines – one for vials, one for prefilled syringes, and one for prefilled pen cartridges.

This volume will tremendously impact the availability and cost of these medicines throughout the country.

Civica is preparing multiple products for FDA approval.

Affordable biosimilar insulins will also be produced in Civica's new facility, ensuring all Americans have access to lower cost, biosimilar insulins, regardless of insurance status.

CIVIC



Our people love knowing the impact we're having to patients and the opportunities we have to serve."

JASON WINFIELD Civica Director of Engineering, <u>Biologics</u>

"Our talented Petersburg team will deliver hundreds of millions of units of essential generic medications as we build capacity and deliver reliable, steady supplies where they are most needed."



BOUWIEN SMITS Civica Petersburg Site Vice President and General Manager



Civica prevents and mitigates drug shortages, ensuring that critical generic medications are available and affordable to all. Because eliminating shortages and high prices is in the best interest of patients. Learn more at <u>CivicaRx.org</u>.